VistaGen Therapeutics Inc. Revenue 2011–2025
VistaGen Therapeutics Inc. annual/quarterly revenue history and growth rate from 2011 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- VistaGen Therapeutics Inc. revenue for the quarter ending December 31, 2025 was 303000, a 29.49% increase year-over-year.
- VistaGen Therapeutics Inc. revenue for the twelve months ending December 31, 2025 was 1.0 M, a 8.68% increase year-over-year.
- VistaGen Therapeutics Inc. annual revenue for 2025 was 486000, a 54.32% decrease from 2024.
- VistaGen Therapeutics Inc. annual revenue for 2024 was 1.1 M, a 568.72% decrease from 2023.
- VistaGen Therapeutics Inc. annual revenue for 2023 was -227000, a 120.47% decrease from 2022.
- VistaGen Therapeutics Inc. annual revenue for 2022 was 1.1 M.
VistaGen Therapeutics Inc. (VTGN) — Frequently Asked Questions
VistaGen Therapeutics Inc. (VTGN) is a publicly traded US company. It has a market capitalization of $17M. In fiscal 2025 it reported revenue of $486,000 and net income of -$51M. Explore VTGN's stock price, financial statements, earnings history, margins and key ratios below.
What is VistaGen Therapeutics Inc.'s market cap?
VistaGen Therapeutics Inc. (VTGN) has a market capitalization of $17M.
What is the VTGN stock price?
VTGN trades at $0.54 (-0.91% on the day).
How much revenue does VistaGen Therapeutics Inc. make?
VistaGen Therapeutics Inc. reported revenue of $486,000 in fiscal 2025.
Is VTGN profitable?
In fiscal 2025, VistaGen Therapeutics Inc. reported net income of -$51M.